No interplay between gut microbiota composition and the lipopolysaccharide-induced innate immune response in humans
16s RNA
LPS
gut microbiota
human endotoxaemia
innate immunity
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
10
2020
revised:
04
03
2021
revised:
26
03
2021
accepted:
26
03
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Animal studies have demonstrated the extensive interplay between the gut microbiota and immunity. Moreover, in critically ill patients, who almost invariably suffer from a pronounced immune response, a shift in gut microbiota composition is associated with infectious complications and mortality. We examined the relationship between interindividual differences in gut microbiota composition and variation in the Healthy male volunteers received an intravenous bolus of 2 ng kg Baseline microbiota composition, analysed by principal coordinate analysis and random forest analysis, did not differ between high and low responders for any of the four measured cytokines. Furthermore, baseline microbiota diversity (Shannon and Chao indices) was similar in high and low responders. No changes in microbiota composition or diversity were observed at 1 and 7 days following the LPS challenge. Our results indicate that existing variation in gut microbiota composition does not explain the observed variability in the LPS-induced innate immune response. These findings strongly argue against the interplay between the gut microbiota composition and the innate immune response in humans.
Identifiants
pubmed: 33968408
doi: 10.1002/cti2.1278
pii: CTI21278
pmc: PMC8082703
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1278Informations de copyright
© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Sci Rep. 2017 Oct 19;7(1):13537
pubmed: 29051531
FEMS Microbiol Ecol. 2013 Aug;85(2):376-88
pubmed: 23614882
J Leukoc Biol. 2008 Mar;83(3):461-6
pubmed: 18160538
Int J Mol Sci. 2018 Jun 06;19(6):
pubmed: 29882798
Cell. 2016 Jun 2;165(6):1551
pubmed: 27259157
mSphere. 2016 Aug 31;1(4):
pubmed: 27602409
Dig Dis Sci. 2011 Apr;56(4):1171-7
pubmed: 20931284
Clin Transl Gastroenterol. 2016 Aug 04;7(8):e186
pubmed: 27489950
Gut Microbes. 2014 May-Jun;5(3):411-8
pubmed: 24922519
Pathol Biol (Paris). 2008 Jul;56(5):305-9
pubmed: 18178333
Nutrients. 2019 Jul 31;11(8):
pubmed: 31370376
Intensive Care Med. 2017 Jan;43(1):59-68
pubmed: 27837233
Shock. 2020 Feb;53(2):171-174
pubmed: 31008870
Gut. 2017 Sep;66(9):1623-1630
pubmed: 27307305
World J Gastroenterol. 2015 Oct 7;21(37):10487-92
pubmed: 26457009
Evol Bioinform Online. 2007 Feb 17;2:121-8
pubmed: 19455206
J Microbiol Biotechnol. 2017 Dec 28;27(12):2089-2093
pubmed: 29032640
Cell. 2016 Nov 3;167(4):1125-1136.e8
pubmed: 27814509
Curr Pharm Des. 2010;16(6):584-96
pubmed: 20388068
EBioMedicine. 2018 Jul;33:144-156
pubmed: 29983349
Nat Med. 2010 Feb;16(2):228-31
pubmed: 20081863
Front Immunol. 2017 Dec 11;8:1600
pubmed: 29312282
Biochimie. 2019 Apr;159:99-106
pubmed: 29936295
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Front Cell Infect Microbiol. 2019 Dec 03;9:409
pubmed: 31850241
Nat Protoc. 2020 Mar;15(3):799-821
pubmed: 31942082
Sci Rep. 2015 Nov 30;5:17441
pubmed: 26616217
J Trauma. 2006 Jan;60(1):126-33
pubmed: 16456446
Arthritis Res Ther. 2015 Jun 07;17:150
pubmed: 26049730
F1000Res. 2016 Jul 22;5:1791
pubmed: 30918626
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188
pubmed: 28449106
Cell Host Microbe. 2014 Mar 12;15(3):374-81
pubmed: 24629343
Trends Microbiol. 2013 May;21(5):221-9
pubmed: 23454077
Gut. 2016 Apr;65(4):575-83
pubmed: 26511795